SCHEMBL3769340

SCHEMBL3769340

Cc1ccccc1C1(O)CCN(CC(=O)N2CCN(C3CCCC3)CC2)CC1

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.49
ALDH1A1 P00352 4/20 0.49
HTT P42858 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
HRH3 Q9Y5N1 4/20 0.44
PARP1 P09874 1/20 0.43
KCNH2 Q12809 2/20 0.43
GRIN2B Q13224 1/20 0.43
RGS12 O14924 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.41
OPRM1 P35372 1/20 0.41
OPRD1 P41143 1/20 0.41
OPRK1 P41145 1/20 0.41
OPRL1 P41146 1/20 0.41
POLB P06746 1/20 0.41
MEN1 O00255 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3771973 0.98 ALDH1A1 (0.46) KDM4EALDH1A1HTTNPSR1HRH3
SCHEMBL3774342 0.81 NPSR1 (0.46) KDM4EALDH1A1HTTNPSR1HRH3
SCHEMBL3767778 0.80 LMNA (0.45) KDM4EALDH1A1HTTNPSR1HRH3
SCHEMBL3772438 0.79 NPSR1 (0.44) KDM4EALDH1A1HTTNPSR1HRH3
SCHEMBL3774214 0.79 TSHR (0.56) KDM4EALDH1A1HTTNPSR1POLB
SCHEMBL3763088 0.78 TSHR (0.58) KDM4EALDH1A1NPSR1POLBMEN1
SCHEMBL20122620 0.78 TSHR (0.58) KDM4EALDH1A1NPSR1POLBMEN1
SCHEMBL3765913 0.77 ALDH1A1 (0.57) KDM4EALDH1A1HTTPOLBMEN1
SCHEMBL3771221 0.77 ALDH1A1 (0.52) KDM4EALDH1A1HTTNPSR1PARP1
SCHEMBL3767749 0.77 SIGMAR1 (0.51) KDM4EALDH1A1HTTNPSR1HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 KDM4E 534/4885ALDH1A1 1210/4885HTT 608/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.